Stay updated with breaking news from Generic Medication. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zydus Lifesciences announced that it has obtained approval from the USFDA to sell a generic medication for the treatment of postherpetic neuralgia. The company has received the final nod from the US Food and Drug Administration (USFDA) to produce and distribute Gabapentin tablets in strengths of 300 mg and 600 mg, as stated in a regulatory filing by Zydus Lifesciences.
India News: Zydus Lifesciences has received approval from the US Food and Drug Administration (USFDA) to market a generic medication to manage postherpetic neuralgia. Read more.
Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "Digital Dose Inhaler Market Size, Share & Trends Analysis Report By Product (MDI, DPI), By Indication...
/PRNewswire/ -- The "Digital Dose Inhaler Market Size, Share & Trends Analysis Report By Product (MDI, DPI), By Indication (Asthma, COPD), By Type (Branded...
JB Chemicals & Pharmaceuticals on Wednesday received approval from the US health regulator to market a generic product, used to treat mood disorders, in the American market. The company's product is the generic version of Pfizer's Sinequan capsules which are indicated for the treatment of anxiety, depression, and other target symptoms of psychoneurosis.